Trevi Therapeutics, Inc. (NASDAQ:TRVI) Short Interest Update

Trevi Therapeutics, Inc. (NASDAQ:TRVI) was the recipient of a large drop in short interest in November. As of November 30th, there was short interest totalling 1,410,000 shares, a drop of 19.4% from the November 15th total of 1,750,000 shares. Based on an average daily volume of 511,500 shares, the days-to-cover ratio is presently 2.8 days.

Institutional Trading of Trevi Therapeutics

Several hedge funds have recently modified their holdings of TRVI. BNP Paribas Financial Markets increased its stake in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after purchasing an additional 6,764 shares in the last quarter. American Century Companies Inc. increased its position in Trevi Therapeutics by 17.1% in the 2nd quarter. American Century Companies Inc. now owns 54,108 shares of the company’s stock valued at $161,000 after buying an additional 7,902 shares in the last quarter. MAI Capital Management raised its stake in Trevi Therapeutics by 0.7% during the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock worth $4,433,000 after buying an additional 8,789 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in Trevi Therapeutics by 87.6% in the second quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after acquiring an additional 11,450 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Trevi Therapeutics in the first quarter valued at approximately $47,000. Institutional investors own 95.76% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on TRVI. Leerink Partners began coverage on Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 price objective on the stock. Raymond James initiated coverage on shares of Trevi Therapeutics in a research note on Friday, August 30th. They issued an “outperform” rating and a $9.00 price target on the stock. D. Boral Capital reiterated a “buy” rating and set a $21.00 price objective on shares of Trevi Therapeutics in a research report on Thursday. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th. Finally, B. Riley reiterated a “buy” rating and set a $6.00 price target on shares of Trevi Therapeutics in a report on Monday, October 7th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Trevi Therapeutics has a consensus rating of “Buy” and a consensus target price of $9.31.

Trevi Therapeutics Trading Up 15.8 %

TRVI stock traded up $0.57 during trading on Friday, hitting $4.17. The company had a trading volume of 4,224,128 shares, compared to its average volume of 592,516. The stock has a market cap of $320.53 million, a PE ratio of -9.48 and a beta of 0.96. The business has a 50-day moving average of $2.99 and a 200-day moving average of $2.93. Trevi Therapeutics has a one year low of $1.22 and a one year high of $4.60.

Trevi Therapeutics (NASDAQ:TRVI) last announced its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period last year, the company earned ($0.08) EPS. Research analysts forecast that Trevi Therapeutics will post -0.49 EPS for the current year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.